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   Examination including residural urine measurement, cystometry and urethral pressure profile 
was performed before and 8 weeks, 3 months and 6 months after the operation in 17 patients with 
rectal cancer who were divided into mecobalamin administered group (8 patients) and non-admin-
istered group (9 patients) at random. Administration of mecobalamin (500 T i.m., 3 times a 
week for 4 weeks) was started within 3 weeks after the operation. 
   In the 17 patients, the rate of patients with residual urine of over 51 ml was 65% at 8 weeks, 
24% at 3 months and 24% at 6 months. The mean value of bladder pressure at maximam capac-
ity after the operation in the 17 patients showed a significant increase compared to that before 
the operation, while the mean value of maximum urethral pressure after the operation showed a 
significant decrease compared to that before the operation. The bladder pressure in patients with 
residual urine less than 50 ml was significantly lower than that in patients with residual urine 
over than 51 ml. The bladder pressure in patients with residual urine reduced to less than 50 ml 
at 3 months showed a tendency to decline. 
   The rate of patients with residual urine of less than 50 ml at 8 weeks was 50% in the meco-
balamin administered group and 22% in the non-administered group. There was no significant 
difference in bladder pressure between the two groups, or before and after the administration of 
mecobalamin. 
                                              (Acta Urol. Jpn. 35: 1853-1857, 1989) 



































それ以後は必要に応 じて種 々の治療薬を使用 した.
Table1.術後排尿効率不良例の頻度









































り変化は認めなかった.な お尿失禁は6ヵ 月で2例 に















































数 値:平 均 値 ± 楳 準偏 差 ・・:pく0,01
村山,ほか:神経因性膀胱 ・直腸癌 1855
Table3.排尿効率良好群 と不良群の比較






















数値:平 均値 ±楳準 偏差 ・:p〈0.05
Table4.排尿効率改善群と不良群の比較



































Table5.術後 排 尿 効 率(Mecobalamin投与 群 と非
投 与 群 の 比較)
投 与 群(8例)非 投与群(9例)
















良好:残 尿 量≦50ml不 良:残 尿量>50ml
Table6.Mecobalamin投与 前 後 の 比 較
































Table7.Mecobalamin投与 群 と非 投 与 群 の 比較






















点をおき,残 尿量50m1以上 とした.し かし残尿量
50m1以下の排尿効率良好症例の中でも軽度の腹圧性












































































た術 後3ヵ 月で残 尿が50ml以下に減少した症 例で
は最大容量時膀胱内圧の低下傾向を認めた.
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